CAMP4 THERAPEUTICS CORP (CAMP)
Health Care · RNA therapeutics / antisense oligonucleotides for rare genetic diseases · NASDAQ
CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy.
What CAMP4 THERAPEUTICS CORP does
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels for treating genetic diseases. The company's lead product candidate, CMP-002, is an intrathecally delivered antisense oligonucleotide targeting SYNGAP1-related disorder, a rare developmental and epileptic encephalopathy. CAMP4's proprietary RAP Platform systematically identifies and characterizes regulatory RNAs (regRNAs) that control gene expression, enabling rapid development of novel ASO candidates to amplify target gene expression in specific tissues.
Themes: ["Gene upregulation / haploinsufficiency","Rare genetic diseases","Developmental and epileptic encephalopathy (DEE)","Central nervous system (CNS) therapeutics","SYNGAP1-related disorder","RNA therapeutics / antisense oligonucleotides"]
Fundamentals
- Price$4.34 as of 2026-07-09 close
- Market cap$218M as of 2026-07-10
- 1-year return+189.0% as of 2026-07-09 close
- Net margin-7.3% as of 2026-07-10
- Gross margin+35.8% as of 2026-07-10
- ROE-194.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+5.6% as of 2026-07-10
- Revenue CAGR (3y)+216.1% SEC XBRL
- Beta-22.76 as of 2026-07-10
Key risks (from latest filing)
["Lead program CMP-002 is still in preclinical/early clinical development with no approved products yet; regulatory approval, clinical trial success, and commercialization remain uncertain","Dependence on third-party manufacturing partners to comply with significant manufacturing regulations; supply chain disruptions could delay development and commercialization","Reliance on intellectual property licensed from third parties; loss of licenses or inability to obtain future licenses on commercially reasonable terms could impair competitive position and product development"]
Competitors & peers
- Antisense Pharma
- Ionis Pharmaceuticals (IONS)
- Stoke Therapeutics
- Reata Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.